We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Mast Group Appointed European Distributor of Kanto Tests

By Labmedica staff writers
Posted on 14 Nov 2006
The Kanto Chemical Company (Tokyo, Japan) has appointed Mast Group Ltd. More...
(Merseyside, UK) as its authorized representative and exclusive European distributor for a range of tests for extended-spectrum beta-lactamase (ESbL) detection.

The Cica Beta products of Kanto incorporate the use of a novel chromogenic compound to differentiate between the various beta lactamase enzymes and permit confirmation of an organism as an ESbL, metallo-beta lactamase (MBL), or AmpC-type lactamase producer. Separate kits are available for each type of beta lactamase enzyme and each kit is color coded for simple identification. The kits can be used individually or in combination for comprehensive enzyme profiling.

Lactamase-producing strains of bacteria are more resistant to antibiotics and cause infections that are difficult to treat. In many instances, only two oral antibiotics and a very limited group of intravenous antibiotics are effective.

Suspect bacterial colonies are streaked onto each strip and identification is made by a clear color change from yellow to red. Results are available within 15 minutes, permitting rapid and accurate identification. The Cica Beta tests supplement the existing range of Mast's identification and antibiotic sensitivity products.

The Cica Beta kits rapidly detect enzyme production in Gram-negative isolates from patients with severe infection. ESbL production by a total of 304 strains of Klebsiella spp., Escherichia coli, and Proteus mirabilis was tested by a Cica Beta kit as well as the phenotypic confirmatory disk test (using cefotaxime and ceftazidime, with and without clavulanate). The kit showed 95.5% and 98.1% sensitivity and specificity, respectively, as compared to the disk test, and thus proved to be an appropriate tool for the rapid detection of ESbL.



Related Links:
Kanto Chemical
Mast Group

Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Gold Member
Genetic Type 1 Diabetes Risk Test
T1D GRS Array
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Whole-genome sequencing enables broader detection of DNA repair defects to guide PARP inhibitor cancer therapy (Photo courtesy of Illumina)

Whole-Genome Sequencing Approach Identifies Cancer Patients Benefitting From PARP-Inhibitor Treatment

Targeted cancer therapies such as PARP inhibitors can be highly effective, but only for patients whose tumors carry specific DNA repair defects. Identifying these patients accurately remains challenging,... Read more

Pathology

view channel
Image: AI models combined with DOCI can classify thyroid cancer subtypes (Photo courtesy of T. Vasse et al., doi 10.1117/1.BIOS.3.1.015001)

AI-Powered Label-Free Optical Imaging Accurately Identifies Thyroid Cancer During Surgery

Thyroid cancer is the most common endocrine cancer, and its rising detection rates have increased the number of patients undergoing surgery. During tumor removal, surgeons often face uncertainty in distinguishing... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.